Cytomegalovirus Antibody, IgG
Also known as: CMV IGG
Use
This test detects past exposure to cytomegalovirus (CMV) by identifying IgG antibodies. It is important for assessing previous infection history, but it is not recommended for diagnosing active or reactivated CMV infections in immunocompromised individuals due to the potential unreliability of serology in these patients. Accurate diagnosis of active CMV requires additional methods such as virus culture or demonstration of viral antigen in cells.
Special Instructions
Specimens should be labeled as 'acute' or 'convalescent.' Parallel testing is preferred, and convalescent specimens must be received within 30 days of receipt of acute specimens.
Limitations
This test is not suitable for blood donor screening, associated re-entry protocols, or for screening human cell, tissues, and cellular- and tissue-based products (HCT/P). In immunocompromised patients, CMV serology may not reliably indicate acute or reactivated CMV disease. The best evidence for current CMV infection is a significant change between two appropriately timed specimens tested in the same laboratory.
FDA ApprovedNew York Approved
Methodology
Immunoassay (CLIA)
Biomarkers
LOINC Codes
- 5124-3
- 5124-3
Result Turnaround Time
1 day
Related Documents
For more information, please review the documents below
Specimen
Serum
Volume
1 mL
Minimum Volume
0.5 mL
Container
Serum separator tube (SST)
Collection Instructions
Allow specimen to clot completely at room temperature. Separate from cells as soon as possible or within 2 hours of collection.
Storage Instructions
Refrigerated
Causes for Rejection
Contaminated, heat-inactivated, icteric, or grossly hemolyzed specimens.
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | 48 hours |
| Refrigerated | 2 weeks |
| Frozen | 1 year (Avoid repeated freeze/thaw cycles) |